Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.3 USD | +0.52% | -0.18% | +16.51% |
03:06pm | Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing | MT |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.51% | 2.01B | |
-9.00% | 11.67B | |
-4.32% | 8B | |
+6.37% | 5.72B | |
+30.86% | 5.5B | |
-14.91% | 3.84B | |
+11.39% | 2.66B | |
-61.57% | 2.66B | |
-9.76% | 2.3B | |
-6.79% | 1.78B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- (MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M